Explore the vast range of titles available.

On the basis of introducing the mechanism of increasing permeability of wetting agent, taking the comprehensive excavation face of hydrophobic and difficult to penetrate coal seam as the test object, through the test of capillary reverse osmosis in the laboratory, the economic and reasonable concentration of 0.6% wetting agent solution for coal seam water injection is determined. In the field, we use clear water and wetting agent solution to carry out the coal seam water injection test, and make a comparative analysis of the technical effect of coal seam water injection. Using clear water to carry out coal seam water injection, the coal seam wetting radius is less than 0.5m, using wetting agent solution to carry out coal seam water injection, the coal seam wetting radius can reach more than 1.5m. The efficiency of water injection with wetting agent solution is 43.06% higher than that with clean water.

Postoperative delirium (POD) and sleep disorders are common surgical complications with a close clinical association, suggesting shared pathophysiological mechanisms mediated by neurotransmitters and neural circuits. Using a mouse model of laparotomy under sevoflurane anesthesia, we assessed delirium-like behaviors (buried food, open field, and Y-maze tests) and sleep alterations (EEG/EMG). Hypothalamic orexin A and midbrain dopamine levels were measured by ELISA. Neural activation was evaluated via c-Fos immunohistochemistry and immunofluorescence staining of lateral hypothalamus (LH) orexin and ventral tegmental area (VTA) dopamine neurons. Tyrosine hydroxylase (TH) expression in the VTA was detected by Western blot. Anesthesia/surgery induced sleep disorders, altered sleep–wake architecture and delirium-like behaviors. Following anesthesia/surgery, c-Fos protein expression was increased in neurons of the LH and ventromedial hypothalamic nucleus (VMH), while it was decreased in sleep-promoting brain regions, including the ventrolateral preoptic area (VLPO) and median preoptic nucleus (MnPO). Additionally, anesthesia/surgery led to increased activation of orexin neurons in the LH and dopamine neurons in the VTA. Hypothalamic orexin A levels and midbrain dopamine concentrations were elevated, along with increased tyrosine hydroxylase (TH) expression in the VTA. Administration of the dual orexin receptor antagonist suvorexant via intraperitoneal injection reduced the activation of VTA dopamine neurons, decreased TH expression, and lowered dopamine levels in these mice. The activation of LH orexin neurons and VTA dopamine neurons is involved in anesthesia/surgery-induced sleep–wake disorders and delirium-like behaviors. The dual orexin receptor antagonist suvorexant ameliorates these abnormalities, highlighting a potential therapeutic target.

Background Long non-coding RNAs (lncRNAs), which are a portion of non-protein-coding RNAs (ncRNAs), have manifested a paramount role in the pathophysiology of human diseases, particularly in pathogenesis and progression of disease. Main body of the abstract Myocardial infarction associated transcript (MIAT), which was recently found to demonstrate aberrant expression in various diseases, such as myocardial infarction, schizophrenia, ischemic stroke, diabetic complications, age-related cataract and cancers, is a novel disease-related lncRNA. This work summarize current evidence regarding the biological functions and underlying mechanisms of lncRNA MIAT during disease development. Short conclusion LncRNA MIAT likely represents a feasible cancer biomarker or therapeutic target.

The gut-brain axis is recognized as a critical pathway through which gut microbiota influences neurological health. However, the complex interplay between gut microbiota composition, blood-brain barrier (BBB) integrity, and cognitive function in elderly individuals with coronary heart disease (CHD) experiencing mild cognitive impairment (MCI) remains insufficiently elucidated. This study aimed to investigate these relationships in a cohort of 40 elderlies with CHD, comparing those with MCI to those with normal cognition (NC), focusing on microbial diversity, specific taxa alterations, BBB permeability, and their correlations with cognitive performance. This preplanned secondary analysis utilized data from two prospective cohort studies, enrolling elderlies with CHD (≥60 years). Participants were categorized into NC (  = 20) and MCI (  = 20) groups based on standardized neuropsychological assessments. Fecal samples underwent 16S rRNA gene sequencing (V3-V4 region) to evaluate gut microbiota diversity and composition. BBB permeability was quantified using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI), specifically measuring the volume transfer constant (Ktrans) in the hippocampus. Compared to the NC group, MCI patients exhibited significantly reduced gut microbial -diversity (Chao1 index:  = 0.002; Shannon index:  = 0.009) and distinct -diversity profiles (Bray-Curtis dissimilarity, PERMANOVA,  = 0.003). LEfSe analysis identified depletion of key short-chain fatty acid (SCFA)-producing taxa in the MCI group, including at the family level (Ruminococcaceae,  = 0.016; Rikenellaceae,  = 0.042; and Barnesiellaceae,  = 0.038) and genus level (Faecalibacterium,  = 0.003 and Oscillospira,  = 0.002). Hippocampal BBB permeability (Ktrans) was significantly elevated in MCI patients (6.04 ± 3.02 vs. 3.90 ± 1.03 × 10 min ,  = 0.006) and inversely correlated with the relative abundance of Faecalibacterium (Spearman's r = -0.466,  = 0.002) and Oscillospira (Spearman's r = -0.322,  = 0.043). Conversely, these genera showed positive correlations with Montreal Cognitive Assessment-Basic (MoCA-B) scores (Faecalibacterium: r = 0.596,  < 0.001; Oscillospira: r = 0.369,  = 0.019). Elderlies with CHD and MCI demonstrate significant gut dysbiosis, characterized by reduced microbial diversity and depletion of SCFA-producing taxa, notably butyrate producers. These microbial alterations are correlated with increased BBB permeability in the hippocampus and diminished cognitive function. These findings highlight the potential role of the gut-brain axis in the pathogenesis of cognitive decline in this vulnerable population and suggest that targeting gut microbiota could be a therapeutic avenue.

Background Accumulating evidence has indicated that long non-coding RNAs (lncRNAs) behave as a novel class of transcription products during multiple cancer processes. However, the mechanisms responsible for their alteration in cholangiocarcinoma (CCA) are not fully understood. Methods The expression of SPRY4-IT1 in CCA tissues and cell lines was determined by RT-qPCR, and the association between SPRY4-IT1 transcription and clinicopathologic features was analyzed. Luciferase reporter and chromatin immunoprecipitation (ChIP) assays were performed to explore whether SP1 could bind to the promoter region of SPRY4-IT1 and activate its transcription. The biological function of SPRY4-IT1 in CCA cells was evaluated both in vitro and in vivo. ChIP, RNA binding protein immunoprecipitation (RIP) and luciferase reporter assays were performed to determine the molecular mechanism of SPRY4-IT1 in cell proliferation, apoptosis and invasion. Results SPRY4-IT1 was abnormally upregulated in CCA tissues and cells, and this upregulation was correlated with tumor stage and tumor node metastasis (TNM) stage in CCA patients. SPRY4-IT1 overexpression was also an unfavorable prognostic factor for patients with CCA. Additionally, SP1 could bind directly to the SPRY4-IT1 promoter region and activate its transcription. Furthermore, SPRY4-IT1 silencing caused tumor suppressive effects via reducing cell proliferation, migration and invasion; inducing cell apoptosis and reversing the epithelial-to-mesenchymal transition (EMT) process in CCA cells. Mechanistically, enhancer of zeste homolog 2 (EZH2) along with the lysine specific demethylase 1 (LSD1) or DNA methyltransferase 1 (DNMT1) were recruited by SPRY4-IT1, which functioned as a scaffold. Importantly, SPRY4-IT1 positively regulated the expression of EZH2 through sponging miR-101-3p. Conclusions Our data illustrate how SPRY4-IT1 plays an oncogenic role in CCA and may offer a potential therapeutic target for treating CCA.

Clemastine, a Food and Drug Administration (FDA)-approved compound, is recognized as a first-generation, widely available antihistamine that reduces histamine-induced symptoms. Evidence has confirmed that clemastine can transport across the blood–brain barrier and act on specific neurons and neuroglia to exert its protective effect. In this review, we summarize the beneficial effects of clemastine in various central nervous system (CNS) disorders, including neurodegenerative disease, neurodevelopmental deficits, brain injury, and psychiatric disorders. Additionally, we highlight key cellular links between clemastine and different CNS cells, in particular in oligodendrocyte progenitor cells (OPCs), oligodendrocytes (OLs), microglia, and neurons.

Background. Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is an invasive procedure that required deep sedation to suppress coughing and body movements. Deep sedation, on the other hand, has been shown to cause respiratory and circulatory depression, especially when the airway is shared with the endoscopist. Esketamine is a novel sedative and analgesic with little respiratory inhibition that appears to be an appropriate adjuvant in propofol sedation for EBUS-TBNA. We compared the efficacy and safety of esketamine combined with propofol target-controlled infusion (TCI) and propofol TCI for deep sedation in EBUS-TBNA. Methods. The study included 135 patients with ASA II-III undergoing EBUS-TBNA. They were randomly divided into two groups (group E and group P). Both groups received midazolam (0.01–0.03 mg/kg) and oxycodone (0.07–0.08 mg/kg). Then, patients in group E received 0.3 mg/kg esketamine, propofol TCI, and 0.2 mg·kg−1·h−1 esketamine for sedative maintenance. Patients in group P received only propofol TCI. The primary outcome was the dose of 1% lidocaine administrated by the endoscopist and the times of lidocaine sprays. Secondary outcome indicators were cough score, propofol dosage, patient satisfaction, endoscopist satisfaction, the incidence of sedation-related adverse effects and side effects, and recovery time. Results. Patients in group E were given significantly less lidocaine (4.36 ml/h (2.67–6.00) vs 6.00 ml/h (4.36–7.20), P<0.001) and less spraying frequency (2.18 times/h (1.33–3.00) vs 3.00 times/h (2.18–3.60), P<0.001) than group P. There was a statistically significant difference in cough score between the two groups (group E 2 (0–4) vs group P 3 (2–4), P=0.03). Also, mean arterial pressure (MAP) was higher in group E in the 30th min (T5, 84.10 ± 12.91 mmHg versus 79.04 ± 10.01 mmHg, P=0.012) and 40th min (T6, 87.72 ± 15.55 mmHg versus 82.14 ± 10.51 mmHg, P=0.026). There were no significant differences between the two groups in terms of sedation-related adverse events and side effects, recovery time, endoscopist satisfaction, and patient satisfaction. Conclusions. In patients with ASA II-III, esketamine as an adjuvant in combination with propofol TCI deep sedation for EBUS-TBNA can improve the sedation effect, reduce coughing reaction during the procedure, and obtain more stable blood pressure. No reduction in the occurrence of sedation-related side effects was observed. This trial is registered with ChiCTR2200061124.

Diabetes mellitus is a metabolic disorder with a complex etiology in which glycemic dynamics are disturbed and the body is unable to maintain the process of glucose homeostasis through the pancreas. Persistent symptoms of high blood glucose or low blood glucose may lead to diabetic complications, such as neuropathy, nephropathy, retinopathy, and cardiovascular diseases. Glycemic variability which can represent the presence of excessive glycemic excursions is an indicator for evaluating glucose homoeostasis. Limiting glycemic variability has gradually become an emerging therapeutic target in improve diabetes metabolism and prevent associated complications. This article reviews the progress of research on the various quantifiable parameters of glycemic variability and their relationships with vascular lesions and mechanisms.

BackgroundLong non-coding RNA (lncRNA) has been testified to influence the initiation and evolution of sundry carcinomas. Recently, lncRNA FOXD2 adjacent opposite strand RNA 1 (FOXD2-AS1) has been found to display vital regulating functions in various cancers.MethodsqRT-PCR was used to verify the dysregulation of FOXD2-AS1 expression in CCA cells and tissues, and the correlation of FOXD2-AS1 expression with clinicopathological characteristics was investigated. The viability, migration, and invasion of CCA cells were verified through CCK-8 assay, colony formation experiment, wound healing assay, and transwell assay. The regulatory networks of FOXD2-AS1 were analyzed by Bioinformatic prediction and dual-luciferase reporter assay.ResultsWe discovered that FOXD2-AS1 was significantly upregulated in CCA and its up-regulation was closely correlated with terminal TNM stage, lymph node metastasis and poor survival in the current research. In addition, it was revealed that FOXD2-AS1 was an independent prognostic factor. Functional tests uncovered that the cell viability, migration, and invasion could be restrained through downregulating the expression of FOXD2-AS1, while FOXD2-AS1 overexpression could facilitate the cell viability, migration, and invasion. Mechanistically, FOXD2-AS1 was founded to interact directly with miR-760 and the oncogene E2F3 was the downstream target of miR-760 through bioinformatic prediction and dual-luciferase reporter assays. Finally, we testified that FOXD2-AS1 could competitively sponge miR-760 and further upregulated the E2F3 expression to play a vital part in cholangiocarcinoma.ConclusionsThis research revealed that lncRNA FOXD2-AS1 could enhance CCA malignant progression through regulating the miR-760/E2F3 axis and was expected to be a prognostic biomarker and therapeutic target for cholangiocarcinoma.

Objective To evaluate the effectiveness of preemptive multimodal analgesiain elderly patients undergoing laparoscopic colorectal surgery. Methods A prospective randomized controlled study was conducted in the Department of Gastrointestinal Surgery of the Second Hospital of Hebei Medical University from January 2022 to December 2022. A total of 133 patients were included according to the criteria and randomly divided into preemptive analgesia (PRA) group (test group, 67patients) and postoperative analgesia (POA) group (control group, 66patients). Results The Visual Analog Scale (VAS)scores of PRA group 24 h, 48 h, and 72 h after operation were lower than those of POA group, and the difference was statistically significant, P < 0.001.The incidences of postoperative gastrointestinal dysfunction (POGD) and postoperative delirium (POD)in PRA group were 13.43% and 8.98%, respectively, which were significantly lower than those in POA group (31.82% and 24.24%), P < 0.05. The levels of IL-6 and IL-10 in PRA group after the operation were 17.54 ± 2.13 ng/L and 15.57 ± 1.71 ng/L respectively, which were lower than those in POA group (25.45 ± 2.95 ng/L and 23.45 ± 1.88 ng/L), P < 0.05. The level of acetylcholinesterase(AchE) was 56.34 ± 5.62 nmol/L in the POA group, which was significantly higher than that in the POA group (49.59 ± 5.52 nmol/L), P < 0.001. Conclusion Preemptive multimodal analgesia can reduce the incidence of POGD and POD in elderly patients undergoing laparoscopic gastrocolic surgery, improve the recovery process of postoperative gastrointestinal function, increase the concentrations of propionic acid and butyric acid in short chain fatty acids (SCFAs) and the number of beneficial intestinal bacteria.